Journal article
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
Abstract
Purpose To establish the recommended phase II dose of the oral γ-secretase inhibitor RO4929097 (RO) in combination with gemcitabine; secondary objectives include the evaluation of safety, tolerability, pharmacokinetics, biomarkers of Notch signaling and preliminary anti-tumor activity. Methods Patients with advanced solid tumors were enrolled in cohorts of escalating RO dose levels (DLs). Tested RO DLs were 20 mg, 30 mg, 45 mg and 90 mg. RO was …
Authors
Richter S; Bedard PL; Chen EX; Clarke BA; Tran B; Hotte SJ; Stathis A; Hirte HW; Razak ARA; Reedijk M
Journal
Investigational New Drugs, Vol. 32, No. 2, pp. 243–249
Publisher
Springer Nature
Publication Date
April 2014
DOI
10.1007/s10637-013-9965-4
ISSN
0167-6997
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdultAgedAmyloid Precursor Protein SecretasesAntineoplastic Combined Chemotherapy ProtocolsBenzazepinesCalcium-Binding ProteinsDeoxycytidineFemaleHumansIntercellular Signaling Peptides and ProteinsMaleMembrane ProteinsMiddle AgedNeoplasmsReceptor, Notch1Receptor, Notch3Receptors, NotchSerrate-Jagged ProteinsGemcitabine